ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 16/707,482

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.

Claims (56)

1 . A method for treating cancer, the method comprising the steps of: (a) administering an anti-cancer therapeutic to a patient, (b) contacting a sample obtained from the patient with an anti-kidney associated antigen 1 (KAAG1) antibody or antigen binding fragment thereof, (c) detecting a complex formed by the antibody or antigen binding fragment thereof and a KAAG1- or KAAG1-variant expressing cell, and (d) administering a further anti-cancer therapeutic.

2 . The method of claim 1 , wherein the anti-cancer therapeutic of step (d) is an anti-KAAG1 antibody or an antigen binding fragment thereof.

3 . The method of claim 1 , wherein the anti-KAAG1 antibody or antigen binding fragment thereof of step (b) is a monoclonal antibody, a chimeric antibody, a hybrid antibody, a humanized antibody or a human antibody or an antigen binding fragment thereof.

4 . The method of claim 1 , wherein the anti-KAAG1 antibody or antigen binding fragment thereof of step (b) comprises a heavy chain variable region comprising the CDRH1 amino acid sequence set forth in SEQ ID NO.:5, the CDRH2 amino acid sequence set forth in SEQ ID NO.:6 or in SEQ ID NO:56 and the CDRH3 amino acid sequence set forth in SEQ ID NO.:7 and a light chain variable region comprising the CDRL1 amino acid sequence set forth in SEQ ID NO.:8, the CDRL2 amino acid sequence set forth in SEQ ID NO.:9 and the CDRL3 amino acid sequence set forth in SEQ ID NO.:10.

5 . The method of claim 1 , wherein the anti-KAAG1 antibody or antigen binding fragment thereof of step (b) comprises:

a. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:41 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:33;

b. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:49 and a light chain having the amino acid sequence set forth in SEQ ID NO.:43;

c. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:38 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:33;

d. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:46 and a light chain having the amino acid sequence set forth in SEQ ID NO.:43;

e. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:39 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:33;

f. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:47 and a light chain having the amino acid sequence set forth in SEQ ID NO.:43;

g. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:40 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:33;

h. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:48 and a light chain having the amino acid sequence set forth SEQ ID NO.:43;

i. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:41 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:34;

j. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:49 and a light chain having the amino acid sequence set forth in SEQ ID NO.:44;

k. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:38 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:34;

l. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:46 and a light chain having the amino acid sequence set forth in SEQ ID NO.:44;

m. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:39 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:34;

n. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:47 and a light chain having the amino acid sequence set forth in SEQ ID NO.:44;

o. a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO.:40 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:34;

p. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:48 and a light chain having the amino acid sequence set forth in SEQ ID NO.:44;

q. a heavy chain variable region having the amino acid sequence set forth SEQ ID NO.:2 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO.:4, or;

r. a heavy chain having the amino acid sequence set forth in SEQ ID NO.:45 and a light chain having the amino acid sequence set forth in SEQ ID NO.:42.

6 . The method of claim 1 , wherein the anti-KAAG1 antibody or antigen binding fragment thereof of step (b) is conjugated with a detectable moiety.

7 . The method of claim 1 , wherein the anti-cancer therapeutic of step (a) comprises an antibody or an antigen binding fragment thereof.

8 . The method of claim 1 , wherein the cancer is selected from the group consisting of ovarian cancer, skin cancer, renal cancer, colorectal cancer, sarcoma, leukemia, brain tumor, thyroid tumor, breast cancer, prostate cancer, oesophageal tumor, bladder tumor, lung tumor and head and neck tumor.

9 . The method of claim 1 , wherein the detection step comprises detecting KAAG1 at the surface of tumor cells.

10 . The method of claim 1 , wherein the detection step is performed on a sample obtained from a patient having or suspected of having cancer.

11 . The method of claim 10 , wherein the sample is a serum sample, a plasma sample, a blood sample or a tissue sample.

12 . A method for treating cancer, the method comprising the steps of: (a) administering a first anti-kidney associated antigen 1 (KAAG1) antibody or antigen binding fragment thereof to a patient, (b) contacting a sample obtained from the patient with a second anti-KAAG1 antibody or antigen binding fragment thereof, (c) detecting a complex formed by the second anti-KAAG1 antibody or antigen binding fragment thereof and a KAAG1- or KAAG1-variant expressing cell, and (d) administering a further anti-cancer therapeutic.

13 . The method of claim 12 , wherein the first anti-KAAG1 antibody or antigen binding fragment thereof is conjugated with a therapeutic moiety.

14 . The method of claim 12 , wherein the second anti-KAAG1 antibody or antigen binding fragment thereof is conjugated with a detectable moiety.

15 . The method of claim 12 , wherein the first and/or second anti-KAAG1 antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising the CDRH1 amino acid sequence set forth in SEQ ID NO.:5, the CDRH2 amino acid sequence set forth in SEQ ID NO.:6 or in SEQ ID NO:56 and the CDRH3 amino acid sequence set forth in SEQ ID NO.:7 and a light chain variable region comprising the CDRL1 amino acid sequence set forth in SEQ ID NO.:8, the CDRL2 amino acid sequence set forth in SEQ ID NO.:9 and the CDRL3 amino acid sequence set forth in SEQ ID NO.:10.

16 . The method of claim 12 , wherein the first and/or second anti-KAAG1 antibody or antigen binding fragment thereof comprises: